Skip to Content
Merck
  • Identification of small molecule inhibitors of G3BP-driven stress granule formation.

Identification of small molecule inhibitors of G3BP-driven stress granule formation.

The Journal of cell biology (2024-01-29)
Brian D Freibaum, James Messing, Haruko Nakamura, Ugur Yurtsever, Jinjun Wu, Hong Joo Kim, Jeff Hixon, Rene Marc Lemieux, Jay Duffner, Walter Huynh, Kathy Wong, Michael White, Christina Lee, Rachel E Meyers, Roy Parker, J Paul Taylor
ABSTRACT

Stress granule formation is triggered by the release of mRNAs from polysomes and is promoted by the action of the RNA-binding proteins G3BP1/2. Stress granules have been implicated in several disease states, including cancer and neurodegeneration. Consequently, compounds that limit stress granule formation or promote their dissolution have potential as both experimental tools and novel therapeutics. Herein, we describe two small molecules, G3BP inhibitor a and b (G3Ia and G3Ib), designed to bind to a specific pocket in G3BP1/2 that is targeted by viral inhibitors of G3BP1/2 function. In addition to disrupting the co-condensation of RNA, G3BP1, and caprin 1 in vitro, these compounds inhibit stress granule formation in cells treated prior to or concurrent with stress and dissolve pre-existing stress granules. These effects are consistent across multiple cell types and a variety of initiating stressors. Thus, these compounds represent powerful tools to probe the biology of stress granules and hold promise for therapeutic interventions designed to modulate stress granule formation.

MATERIALS
Product Number
Brand
Product Description

Roche
cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial
Roche
Anti-GFP, from mouse IgG1κ (clones 7.1 and 13.1)
Sigma-Aldrich
Anti-Puromycin Antibody, clone 12D10, clone 12D10, from mouse